182 related articles for article (PubMed ID: 26683340)
21. Tuberous sclerosis complex 1-mechanistic target of rapamycin complex 1 signaling determines brown-to-white adipocyte phenotypic switch.
Xiang X; Lan H; Tang H; Yuan F; Xu Y; Zhao J; Li Y; Zhang W
Diabetes; 2015 Feb; 64(2):519-28. PubMed ID: 25213336
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of p53 mutation in pancreatic acinar cell carcinomas of humans and transgenic mice.
Terhune PG; Memoli VA; Longnecker DS
Pancreas; 1998 Jan; 16(1):6-12. PubMed ID: 9436856
[TBL] [Abstract][Full Text] [Related]
23. miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma.
Wang Y; Zhang X; Tang W; Lin Z; Xu L; Dong R; Li Y; Li J; Zhang Z; Li X; Zhao L; Wei JJ; Shao C; Kong B; Liu Z
Cell Death Differ; 2017 Dec; 24(12):2089-2100. PubMed ID: 28800130
[TBL] [Abstract][Full Text] [Related]
24. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex signaling axis in adenoid cystic carcinoma.
Sun ZJ; Chen G; Zhang W; Hu X; Liu Y; Zhou Q; Zhu LX; Zhao YF
Mol Pharmacol; 2011 Jan; 79(1):106-18. PubMed ID: 20959361
[TBL] [Abstract][Full Text] [Related]
25. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
26. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
27. In Vivo Senescence in the Sbds-Deficient Murine Pancreas: Cell-Type Specific Consequences of Translation Insufficiency.
Tourlakis ME; Zhang S; Ball HL; Gandhi R; Liu H; Zhong J; Yuan JS; Guidos CJ; Durie PR; Rommens JM
PLoS Genet; 2015 Jun; 11(6):e1005288. PubMed ID: 26057580
[TBL] [Abstract][Full Text] [Related]
28. Regulation of mast cell survival and function by tuberous sclerosis complex 1.
Shin J; Pan H; Zhong XP
Blood; 2012 Apr; 119(14):3306-14. PubMed ID: 22362037
[TBL] [Abstract][Full Text] [Related]
29. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
30. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
[TBL] [Abstract][Full Text] [Related]
31. p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
Akeno N; Miller AL; Ma X; Wikenheiser-Brokamp KA
Oncogene; 2015 Jan; 34(5):589-99. PubMed ID: 24469052
[TBL] [Abstract][Full Text] [Related]
32. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
[TBL] [Abstract][Full Text] [Related]
33. Death-associated protein kinase 1 promotes growth of p53-mutant cancers.
Zhao J; Zhao D; Poage GM; Mazumdar A; Zhang Y; Hill JL; Hartman ZC; Savage MI; Mills GB; Brown PH
J Clin Invest; 2015 Jul; 125(7):2707-20. PubMed ID: 26075823
[TBL] [Abstract][Full Text] [Related]
34. TSC1/mTOR-controlled metabolic-epigenetic cross talk underpins DC control of CD8+ T-cell homeostasis.
Shi L; Chen X; Zang A; Li T; Hu Y; Ma S; Lü M; Yin H; Wang H; Zhang X; Zhang B; Leng Q; Yang J; Xiao H
PLoS Biol; 2019 Aug; 17(8):e3000420. PubMed ID: 31433805
[TBL] [Abstract][Full Text] [Related]
35. The TSC1-mTOR-PLK axis regulates the homeostatic switch from Schwann cell proliferation to myelination in a stage-specific manner.
Jiang M; Rao R; Wang J; Wang J; Xu L; Wu LM; Chan JR; Wang H; Lu QR
Glia; 2018 Sep; 66(9):1947-1959. PubMed ID: 29722913
[TBL] [Abstract][Full Text] [Related]
36. Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling.
Matthew EM; Yang Z; Peri S; Andrake M; Dunbrack R; Ross E; El-Deiry WS
Neoplasia; 2018 Mar; 20(3):244-255. PubMed ID: 29448085
[TBL] [Abstract][Full Text] [Related]
37. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.
Martinelli P; Madriles F; Cañamero M; Pau EC; Pozo ND; Guerra C; Real FX
Gut; 2016 Mar; 65(3):476-86. PubMed ID: 25596178
[TBL] [Abstract][Full Text] [Related]
38. p53 and rapamycin are additive.
Christy B; Demaria M; Campisi J; Huang J; Jones D; Dodds SG; Williams C; Hubbard G; Livi CB; Gao X; Weintraub S; Curiel T; Sharp ZD; Hasty P
Oncotarget; 2015 Jun; 6(18):15802-13. PubMed ID: 26158292
[TBL] [Abstract][Full Text] [Related]
39. mTOR promotes pituitary tumor development through activation of PTTG1.
Chen R; Duan J; Li L; Ma Q; Sun Q; Ma J; Li C; Zhou X; Chen H; Jing Y; Zhao S; Wu X; Zhang H
Oncogene; 2017 Feb; 36(7):979-988. PubMed ID: 27524416
[TBL] [Abstract][Full Text] [Related]
40. The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis.
Bellizzi AM; Bloomston M; Zhou XP; Iwenofu OH; Frankel WL
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):442-7. PubMed ID: 20661135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
